Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
Type:
Grant
Filed:
July 20, 2017
Date of Patent:
October 25, 2022
Assignee:
Hadasit Medical Research Services and Development Ltd.
Inventors:
Iris Lavon Ben Moshe, Tamar Canello Avramovitch
Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.
Type:
Grant
Filed:
July 13, 2018
Date of Patent:
October 11, 2022
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Yuval Dor, Ruth Shemer, Benjamin Glaser, Judith Magenheim
Abstract: A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.
Type:
Application
Filed:
June 11, 2020
Publication date:
July 28, 2022
Applicant:
Hadasit Medical Research Services and Development Ltd.
Inventors:
Benjamin Eithan REUBINOFF, Etti BEN-SHUSHAN
Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.
Type:
Application
Filed:
November 22, 2021
Publication date:
July 21, 2022
Applicants:
NOBIO Ltd., Hadasit Medical Research Services and Development Ltd.
Abstract: A culture of human pluripotent stem cells (hPSCs) is disclosed. In the culture, more than 50% of the hPSCs are formative hPSCs and are capable of renewing. Uses thereof are also disclosed.
Type:
Application
Filed:
May 22, 2020
Publication date:
July 7, 2022
Applicant:
Hadasit Medical Research Services and Development Ltd.
Inventors:
Benjamin Eithan REUBINOFF, Michal GROPP
Abstract: A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70% of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.
Type:
Application
Filed:
February 28, 2022
Publication date:
June 16, 2022
Applicants:
Yeda Research and Development Co. Ltd., Hadasit Medical Research Services and Development Ltd.
Inventors:
Eran ELINAV, Yotam COHEN, Ahinoam LEV-SAGIE, Debra GOLDMAN-WOHL
Abstract: Device for accessing a pericardial space of a subject in need thereof, the device including a tubular member having an atraumatic distal end and a thread formed on, and at least partially around, the outer surface of the tubular member, proximally to the distal end; wherein the thread is configured to cut, puncture and/or penetrate a pericardium.
Type:
Grant
Filed:
June 17, 2018
Date of Patent:
April 12, 2022
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Ran Eliaz, Yonathan Avraham Demma, Ziv Menshes, Or Hazan, Eva Abramov, Yaakov Nahmias, Amnon Buxboim, Yoav Kan-Tor, Yoav Mintz, Elchanan Fried
Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
March 15, 2022
Assignee:
Hadasit Medical Research Services and Development Ltd.
Inventors:
Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.
Type:
Grant
Filed:
January 31, 2017
Date of Patent:
March 1, 2022
Assignee:
Hadasit Medical Research Services and Development Ltd.
Inventors:
Ithai Waldhorn, Benjamin Eithan Reubinoff
Abstract: The present invention is directed to a method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an adropin stimulating agent. Further provided are a method and a kit for diagnosing or prognosing liver metastases in a subject.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
February 15, 2022
Assignee:
HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
Abstract: A guided tracheal intubation system using an autonomous modulated light source, outputting modulated illumination at a constant level, and externally applied to the subject's larynx region. An optical imaging system receives a video stream from within the subject's throat, including modulated illumination from the subject's trachea. A display control system performs signal processing on the modulated content of the images, and outputs frames of those images in which the intensity level of illumination from the trachea can be controlled without any need to change the illumination output from the modulated light source. The light source has no connection with the rest of the system, and need contain no more than a battery, a power supply circuit and a light source. It can therefore be of low cost and can be made disposable, such as in the form of an adhesive patch applied to the subject's neck.
Type:
Grant
Filed:
May 16, 2014
Date of Patent:
February 8, 2022
Assignees:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
Type:
Grant
Filed:
July 28, 2016
Date of Patent:
January 25, 2022
Assignee:
Hadasit Medical Research Services and Development Ltd.
Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
Type:
Application
Filed:
July 29, 2021
Publication date:
January 13, 2022
Applicant:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.
Type:
Grant
Filed:
April 14, 2015
Date of Patent:
December 21, 2021
Assignees:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Inventors:
Yuval Dor, Ruth Shemer, Benjamin Glaser
Abstract: The present invention relates to heparanase-neutralizing monoclonal antibodies (m Abs), pharmaceutical composition comprising same, and use thereof for treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, diabetes and related complications. The present invention further provides combined therapies comprising the heparanase-neutralizing m Ab and an anti-cancer treatment such as chemotherapy or radiation, for treating a proliferative disease in a subject.
Type:
Grant
Filed:
October 13, 2016
Date of Patent:
November 2, 2021
Assignees:
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Israel Vlodavsky, Marina Weissmann, Neta Ilan, Gil Arvatz
Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
Type:
Grant
Filed:
May 9, 2019
Date of Patent:
August 24, 2021
Assignee:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT
LTD.
Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
Type:
Grant
Filed:
August 28, 2019
Date of Patent:
August 17, 2021
Assignees:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
Inventors:
Bernard Lerer, Mugesh Govindasamy, Tzuri Lifschytz
Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.
Type:
Grant
Filed:
February 22, 2018
Date of Patent:
July 6, 2021
Assignees:
Hadasit Medical Research Services and Development Ltd., Ramot at Tel-Aviv University Ltd.
Inventors:
Or Kakhlon, Miguel Enrique Weil, Leonardo Javier Solmesky
Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
Type:
Grant
Filed:
February 20, 2018
Date of Patent:
June 15, 2021
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Dan Deutsch, Amir Haze, Anat Blumenfeld